TABLE 1.
Regional Susceptibilities Among 20 DICON Hospitals
| Pathogen | Test | No. of Isolates Tested (No. of Hospitals Reporting) | Hospitals Reporting <30 Isolates, No. (%) | Regional Mean % Susceptible (95% CI) | Hospitals Within 1 SD, No. (%) | Hospitals Within 2 SD, No. (%) | Hospitals > 1 SD Below Mean Regional Susceptibility, No. (%) | Hospitals > 2 SD Below Mean Regional Susceptibility, No. (%) |
|---|---|---|---|---|---|---|---|---|
| Escherichia coli | FQ | 27,428 (20) | 0 (0) | 71 (62–81) | 14 (70) | 19 (95) | 3 (15) | 1 (5) |
| E. coli | TMP/SMX | 27,425 (20) | 0 (0) | 70 (61–80) | 15 (75) | 19 (95) | 3 (15) | 0 (0) |
| Proteus mirabilis | FQ | 4,607 (20) | 1 (5) | 66 (48–84) | 13 (65) | 19 (95) | 4 (20) | 1 (5) |
| Pseudomonas aeruginosa | FQ | 3,509 (19) | 1 (5) | 70 (57–83) | 13 (68) | 18 (95) | 1 (5) | 1 (5) |
| P. aeruginosa | Pip/Tazo | 2,878 (17) | 1 (6) | 89 (74–100) | 13 (76) | 16 (94) | 2 (12) | 1 (6) |
| Enterobacter cloacae | FQ | 1,213 (18) | 4 (22) | 88 (74–100) | 11 (61) | 17 (94) | 4 (22) | 1 (6) |
| E. cloacae | Carb | 1,100 (17) | 4 (24) | 98 (94–100) | 14 (82) | 17 (100) | 3 (18) | 0 (0) |
| Citroboacter freundii | FQ | 437 (12) | 7 (58) | 85 (72–98) | 8 (67) | 12 (100) | 1 (8) | 0 (0) |
| Acinetobacter baumannii | Amp/Sul | 296 (7) | 3 (43) | 80 (58–100) | 4 (57) | 7 (100) | 2 (29) | 0 (0) |
| A. baumannii | Carb | 311 (8) | 4 (50) | 69 (30–100) | 4 (50) | 8 (100) | 1 (13) | 0 (0) |
| Morganella morganii | FQ | 226 (6) | 3 (50) | 61 (44–79) | 4 (67) | 6 (100) | 1 (17) | 0 (0) |
| Stenotrophomonas maltophilia | TMP/SMX | 174 (7) | 5 (71) | 93 (83–100) | 4 (57) | 7 (100) | 1 (14) | 0 (0) |
| S. maltophilia | Levo | 174 (7) | 5 (71) | 81 (66–96) | 5 (71) | 7 (100) | 1 (14) | 0 (0) |
NOTE. DICON, Duke Infection Control Outreach Network; FQ, fluoroquinolone; Pip/Tazo, piperacillin/tazobactam; TMP/SMX, trimethoprim/sulfamethoxazole; Levo, levofloxacin; Amp/Sul, ampicillin/sulbactam; Carb, carbapenem.